{
  "text": "Aggressive systemic mastocytosis and malignant histiocytosis share underlying mechanisms that contribute to their comorbidity.",
  "status": "processed",
  "additional_info": "{\"supportingPapers\": [{\"title\": \"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma\", \"authors\": [{\"name\": \"Vignesh Shanmugam\", \"hIndex\": 15}, {\"name\": \"Gabriel K. Griffin\", \"hIndex\": 25}, {\"name\": \"Eric Jacobsen\", \"hIndex\": 50}, {\"name\": \"Christopher D.\\ufffdM. Fletcher\", \"hIndex\": 151}], \"link\": \"https://www.nature.com/articles/s41379-018-0200-x.pdf\", \"relevance\": 0.7, \"weight_score\": 0.647, \"excerpts\": [\"We identified recurrent mutations involving the RAS-MAPK signaling pathway (MAP2K1, KRAS, NRAS, BRAF, PTPN11, NF1, CBL) in a majority (57%) of histiocytic sarcoma cases.\", \"Further, a subset of histiocytic sarcoma cases shows striking molecular genetic similarities to B cell lymphomas, supporting a clonal relationship between B cell neoplasms and a subset of histiocytic sarcomas.\", \"These findings support a cooperative role for MAPK, PI3K, and cyclin-CDK4/6-INK4 signaling in the pathogenesis of histiocytic sarcoma and provide a rational basis for targeting these pathways.\"], \"explanations\": [\"The paper discusses the genetic mutations and pathways involved in histiocytic sarcoma, particularly focusing on the RAS-MAPK and PI3K-AKT-MTOR pathways, which are also implicated in other hematologic neoplasms.\", \"The study identifies a subset of histiocytic sarcomas that show genetic similarities with B cell lymphomas, suggesting a potential clonal relationship, which could imply shared mechanisms with other aggressive neoplasms like systemic mastocytosis.\", \"The paper highlights the role of RAS-MAPK pathway mutations in histiocytic sarcoma, which is a pathway also involved in systemic mastocytosis, suggesting a possible shared mechanism.\"], \"citations\": [{\"text\": \"We identified recurrent mutations involving the RAS-MAPK signaling pathway (MAP2K1, KRAS, NRAS, BRAF, PTPN11, NF1, CBL) in a majority (57%) of histiocytic sarcoma cases.\", \"page\": 1, \"citation\": \"TY  - JOUR\\n        TI  - Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma\\n        AU  - Vignesh Shanmugam and Gabriel K. Griffin and Eric Jacobsen and Christopher D.\\ufffdM. Fletcher\\n        PY  - 2019\\n        JO  - Modern Pathology\\n        UR  - https://www.nature.com/articles/s41379-018-0200-x.pdf\\n        SP  - 1\\n        ER  -\"}, {\"text\": \"Further, a subset of histiocytic sarcoma cases shows striking molecular genetic similarities to B cell lymphomas, supporting a clonal relationship between B cell neoplasms and a subset of histiocytic sarcomas.\", \"page\": 1, \"citation\": \"TY  - JOUR\\n        TI  - Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma\\n        AU  - Vignesh Shanmugam and Gabriel K. Griffin and Eric Jacobsen and Christopher D.\\ufffdM. Fletcher\\n        PY  - 2019\\n        JO  - Modern Pathology\\n        UR  - https://www.nature.com/articles/s41379-018-0200-x.pdf\\n        SP  - 1\\n        ER  -\"}, {\"text\": \"These findings support a cooperative role for MAPK, PI3K, and cyclin-CDK4/6-INK4 signaling in the pathogenesis of histiocytic sarcoma and provide a rational basis for targeting these pathways.\", \"page\": 1, \"citation\": \"TY  - JOUR\\n        TI  - Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma\\n        AU  - Vignesh Shanmugam and Gabriel K. Griffin and Eric Jacobsen and Christopher D.\\ufffdM. Fletcher\\n        PY  - 2019\\n        JO  - Modern Pathology\\n        UR  - https://www.nature.com/articles/s41379-018-0200-x.pdf\\n        SP  - 1\\n        ER  -\"}]}], \"nonRelevantPapers\": [{\"title\": \"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation\", \"authors\": [{\"name\": \"Nami Nakagomi\", \"hIndex\": 14}, {\"name\": \"Seiichi Hirota\", \"hIndex\": 59}], \"link\": \"https://www.nature.com/articles/3700524.pdf\", \"explanation\": \"The paper focuses on the genetic mutations and drug resistance in aggressive systemic mastocytosis, specifically related to the c-kit gene. It does not address malignant histiocytosis or any shared mechanisms between ASM and malignant histiocytosis, which is the core of the claim.\"}, {\"title\": \"Recent Developments in the Maytansinoid Antitumor Agents\", \"authors\": [{\"name\": \"John M. Cassady\", \"hIndex\": 34}, {\"name\": \"Kenneth K. Chan\", \"hIndex\": 54}, {\"name\": \"Heinz G. Floss\", \"hIndex\": 62}, {\"name\": \"Eckhard Leistner\", \"hIndex\": 34}], \"link\": \"https://www.jstage.jst.go.jp/article/cpb/52/1/52_1_1/_pdf\", \"explanation\": \"The paper focuses on the chemistry and biology of maytansinoid antitumor agents, which are unrelated to the claim about shared mechanisms between aggressive systemic mastocytosis and malignant histiocytosis. There is no mention of these diseases or their comorbidity in the paper.\"}, {\"title\": \"Signaling and regulation of G protein-coupled receptors in airway smooth muscle\", \"authors\": [{\"name\": \"Charlotte K. Billington\", \"hIndex\": 25}, {\"name\": \"Raymond B. Penn\", \"hIndex\": 47}], \"link\": \"https://respiratory-research.biomedcentral.com/track/pdf/10.1186/1465-9921-4-2\", \"explanation\": \"The paper focuses on the signaling and regulation of G protein-coupled receptors in airway smooth muscle, particularly in the context of asthma and airway diseases. It does not discuss aggressive systemic mastocytosis, malignant histiocytosis, or any shared underlying mechanisms between these conditions. Therefore, it is not relevant to the claim about the comorbidity of aggressive systemic mastocytosis and malignant histiocytosis.\"}, {\"title\": \"Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease\", \"authors\": [{\"name\": \"Angelos Halaris\", \"hIndex\": 39}], \"link\": \"https://doi.org/10.1007/7854_2016_28\", \"explanation\": \"The paper discusses the comorbidity between cardiovascular disease and depressive illness, focusing on the mechanisms such as autonomic nervous system imbalance, immune dysregulation, and inflammation. It does not address aggressive systemic mastocytosis or malignant histiocytosis, nor does it explore any shared mechanisms between these conditions. Therefore, the content is not relevant to the claim about the comorbidity and shared mechanisms between aggressive systemic mastocytosis and malignant histiocytosis.\"}, {\"title\": \"Bone marrow and bone: a functional unit\", \"authors\": [{\"name\": \"JE Compston\", \"hIndex\": 0}], \"link\": \"https://joe.bioscientifica.com/downloadpdf/journals/joe/173/3/387.pdf\", \"explanation\": \"The paper primarily discusses the functional relationship between bone and bone marrow, focusing on bone remodelling, the role of various cells in this process, and the impact of different diseases on bone structure. It does not address the specific mechanisms underlying aggressive systemic mastocytosis and malignant histiocytosis or their potential comorbidity. Therefore, it does not provide information relevant to the claim about shared underlying mechanisms between these two conditions.\"}, {\"title\": \"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms\", \"authors\": [{\"name\": \"Joseph D. Khoury\", \"hIndex\": 56}, {\"name\": \"\\u00c9ric Solary\", \"hIndex\": 97}, {\"name\": \"Oussama Abla\", \"hIndex\": 31}, {\"name\": \"Yassmine Akkari\", \"hIndex\": 25}], \"link\": \"https://www.nature.com/articles/s41375-022-01613-1.pdf\", \"explanation\": \"The paper is a review of the WHO classification of haematolymphoid tumors, focusing on taxonomy, diagnostic criteria, and classification updates. It does not discuss the underlying mechanisms or comorbidity between aggressive systemic mastocytosis and malignant histiocytosis, which is the focus of the claim.\"}, {\"title\": \"The need to differentiate Campylobacter fetus subspecies isolated from humans\", \"authors\": [{\"name\": \"Wiltrud M. Kalka-Moll\", \"hIndex\": 21}, {\"name\": \"M.A.P. van Bergen\", \"hIndex\": 13}, {\"name\": \"Georg Plum\", \"hIndex\": 32}, {\"name\": \"Martin Kr\\u00f6nke\", \"hIndex\": 77}], \"link\": \"http://www.clinicalmicrobiologyandinfection.com/article/S1198743X14622503/pdf\", \"explanation\": \"The paper focuses on the identification, epidemiology, and pathogenicity of Campylobacter species, particularly Campylobacter fetus, and does not discuss aggressive systemic mastocytosis, malignant histiocytosis, or any shared mechanisms between these conditions. Therefore, it is not relevant to the claim about the comorbidity mechanisms of aggressive systemic mastocytosis and malignant histiocytosis.\"}, {\"title\": \"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis\", \"authors\": [{\"name\": \"Bj\\u00f6rn van Anrooij\", \"hIndex\": 14}, {\"name\": \"Hanneke C. Kluin\\u2010Nelemans\", \"hIndex\": 83}, {\"name\": \"M. Safy\", \"hIndex\": 6}, {\"name\": \"Bertine M.J. Flokstra-de Blok\", \"hIndex\": 31}], \"link\": \"https://doi.org/10.1111/all.12920\", \"explanation\": \"The paper focuses on the development and validation of quality-of-life and symptom assessment tools for patients with mastocytosis. It does not discuss the underlying mechanisms of aggressive systemic mastocytosis or malignant histiocytosis, nor does it address any potential comorbidity or shared mechanisms between these conditions.\"}], \"inaccessiblePapers\": [], \"explanation\": \"The claim that aggressive systemic mastocytosis and malignant histiocytosis share underlying mechanisms contributing to their comorbidity is partially supported by the evidence provided. The paper by Shanmugam et al. identifies recurrent mutations in the RAS-MAPK signaling pathway in a significant portion of histiocytic sarcoma cases. This pathway is known to be involved in various cellular processes, including proliferation and survival, and its dysregulation is a common feature in many cancers. The identification of these mutations suggests a potential mechanistic overlap with other neoplasms, including those involving mast cells, which are implicated in systemic mastocytosis.\\n\\nHowever, the evidence does not directly address systemic mastocytosis or its specific molecular mechanisms. The paper focuses on histiocytic sarcoma and its genetic similarities to B cell lymphomas, rather than directly linking it to mastocytosis. While the RAS-MAPK pathway is a common signaling route in many cancers, the paper does not provide direct evidence of its role in systemic mastocytosis or its comorbidity with histiocytic sarcoma. Additionally, the relevance and reliability weights of the paper suggest moderate support, indicating that while the findings are significant, they are not conclusive for the claim in question.\\n\\nIn conclusion, while the evidence suggests a potential overlap in the molecular mechanisms of histiocytic sarcoma and other neoplasms, it does not directly support the specific claim regarding systemic mastocytosis. The claim is therefore only weakly supported by the available evidence, as the direct connection between the two conditions is not established in the provided paper. The claim rating is thus a 2, reflecting limited support based on the current evidence.\", \"claimRating\": 2, \"usage_stats\": {\"prompt_tokens\": 449, \"completion_tokens\": 356, \"total_tokens\": 805, \"total_cost\": 0.0047}}"
}